Discover what works (and what doesn’t work) in the areas of drug prevention, treatment, harm reduction and social reintegration (EMCDDA)
Bibliography: Interventions – Treatment
Turning evidence into practice: Preventing blood-borne viruses
This briefing aims to support local authorities and drug treatment and healthcare services to review their BBV prevention and treatment interventions for people who inject drugs (Public Health England)
Methamphetamine 2015
17 points (Australian Medical Association)
Cannabis: the Irish situation
How many people use cannabis in Ireland? (NDC)
Challenges & Opportunities
Key findings from VAADA’s Alcohol and Other Drug (AOD)Sector Recommissioning Survey (VAADA)
Drug-related hospital stays in Australia 1993-2013
This bulletin presents data on drug-related hospital separations in Australia from 1993-2013 for the following drug types: opioids, cocaine, amphetamines and cannabis (NDARC)
Final Report: The Recovery Partnership Review of Alcohol Treatment Services
This is the report on the Recovery Partnership review of the current state of alcohol treatment in England
Public health functions to be exercised by NHS England
Public health services for people in prison or other places of detention, including those held in the Children &Young People’s Secure Estate (Public Health England)
Draft Council conclusions on the implementation of the EU Action Plan on Drugs 2013-2016
Regarding minimum quality standards in drug demand reduction in the European Union
Improving access to, and completion of, hepatitis C treatment
This briefing provides an overview of the key issues that local providers and commissioners of drug and hepatitis treatment should consider (PHE)
World Drug Report 2015
UNODC
National opioid pharmacotherapy statistics 2014
On a snapshot day in 2014, over 48,000 clients received pharmacotherapy treatment for their opioid dependence at 2,432 dosing points around Australia (AIHW)
Alcohol and other drug treatment services in Australia 2013–14
Over the 5 years from 2009–10, there has been an increase in the proportion of episodes where amphetamines were the principal drug on concern (from 7% to 17%) and an increase in smoking/inhaling as the method of administration for amphetamines. A majority of treatment episodes had a duration of three months or less, and counselling remains the most common treatment type (AIHW)
Position paper on the provision of low threshold residential stabilisation services in Ireland
(Ana Liffey drug project)
Methadone Dose-capping Still Continues in Practice, If Not in Policy
Dose-capping – limiting the amount of methadone a patient can take on a daily basis – was ruled “contrary to the current state of the medical literature and the principle of individualized treatment” in 2007 by SAMHSA in the Federal Guidelines for Opioid Treatment. So it’s surprising that it still goes on (ATF)
20 year report on Needle and Syringe Program attendees in Australia
The report presents national and jurisdictional data from the Australian Needle and Syringe Program Survey from 1995 to 2014. Around two thirds of Australia’s primary Needle and Syringe Program services participate in the survey and program attendees have participated on more than 45,000 occasions (The Kirby Institute, UNSW Australia)
IMO launches major policy paper on Addiction and Dependency
The paper addresses a range of issues including prevention and treatment issues (Irish Medical Organisation)
The misuse of benzodiazepines among high-risk opioid users in Europe
As we describe below, available evidence shows that the misuse of benzodiazepines contributes to morbidity and mortality among high-risk opioid users (EMCDDA)
Global policy and access to new hepatitis C therapies for people who inject drugs
This review outlines policy recommendations made in the 2014 World Health Organisation (WHO) Guidelines on Screening, Care and Treatment of HCV and their relevance to PWID (Drug Policy)
Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial
Continuation of methadone maintenance during incarceration could contribute to greater treatment engagement after release, which could in turn reduce the risk of death from overdose and risk behaviours (The Lancet)